In addition, our previous study showed that overexpression of PDE4D in mouse liver played a key role in NAFLD by promoting the expression of the fatty acid uptake gene CD36, which could be reversed by the selective PDE4 inhibitor roflumilast [15]. This evidence concerns the gene PDE4D and metabolic dysfunction-associated steatotic liver disease.